奥氮平致非典型的抗精神病药恶性综合征  

Olanzapine-induced atypical neuroleptic malignant syndrome

作　　者：邱晓燕[1] 戚玮琳[2] 王大猷[1] 

机构地区：[1]复旦大学附属华山医院药剂科,上海200040 [2]复旦大学附属华山医院心内科,上海200040

出　　处：《药物不良反应杂志》2010年第6期438-439,共2页Adverse Drug Reactions Journal

摘　　要：1例73岁女性精神分裂症患者,口服氯丙嗪(早150 mg、晚100 mg)及苯海索(4 mg,2次/d)治疗30年,加用奥氮平10 mg,1次/d口服2个月后出现CK升高,达15 570 U/L,同时伴发热、肌张力增高、心动过速,P 105次/min。停用奥氮平,继续应用氯丙嗪及苯海索,并给予对症支持治疗,CK水平逐渐下降至接近正常值。停药第19天患者自行应用奥氮平10 mg,1次/d,4 d后CK再次升高达700 U/L,停药后恢复正常。A 73-year-old schizophrenic wom an received chlorpromazine（150 mg in morning,100 mg at night） and benzhexol（4 mg twice daily） for 30 years.Olanzapine 10 mg twice daily was added to the regimen.Two months later,the patient presented with creatine kinase elevation, acheiving a level of 15 570 U/L,and accompanied by fever,hypermyotonia,tachy cardia and a pulse of 105 beats/min.Olanzapine was withdrawn and chlorpromazine and benzhexol were continued,meanwhile symptomatic and supportive treatments were given,her creatine kinase level gradually decreased close to normal level. On day 19 after drug discontinuation,the patient self-medicated with olanzapine 10 mg once daily,the creatine kinase level increased again,acheiving a level of 700 U/L,and then normalized after drug discontinuation.

关 键 词：奥氮平 不良反应 抗精神病药恶性综合征 

分 类 号：R749.3[医药卫生—神经病学与精神病学]